Acute coronary syndrome in patients with type 2 diabetes mellitus

  • Authors: Ametov A.S.1, P'yanykh O.P.1, Aslandziya E.N.1, Ametov AS2, Pianykh OP2, Aslandzia EN2
  • Affiliations:
    1. Russian Medical Academy of Advanced Medical Training, Moscow
  • Issue: Vol 83, No 9 (2011)
  • Pages: 66-70
  • Section: Editorial
  • URL: https://ter-arkhiv.ru/0040-3660/article/view/30937
  • Cite item

Abstract


According to evidence obtained from large epidemiological studies, an incidence rate of acute coronary syndrome (ACS) in diabetics is 2-3 times higher than in general population. Relevant invalidity and mortality is much higher than in patients free of diabetes. In type 2 diabetes mellitus a high risk of an unfavourable course and outcome of myocardial infarction was registered both within 30 postinfarction days and 1-3 years of follow-up.Poor prognosis persists despite adequate and early treatment. The results of the attempts to correct MI prognosis in diabetics by means of carbohydrate metabolism correction (multicenter trials DIGAMI-1, DIGAMI-2) are reviewed.

About the authors

Aleksandr Sergeevich Ametov

Email: alexander.ametov@gmail.com

Ol'ga Pavlovna P'yanykh

Email: docror-olga.p@mail.ru

Esma Nodarovna Aslandziya

Email: esmin2007@yandex.ru

A S Ametov

Russian Medical Academy of Advanced Medical Training, Moscow

Russian Medical Academy of Advanced Medical Training, Moscow

O P Pianykh

Russian Medical Academy of Advanced Medical Training, Moscow

Russian Medical Academy of Advanced Medical Training, Moscow

E N Aslandzia

Russian Medical Academy of Advanced Medical Training, Moscow

Russian Medical Academy of Advanced Medical Training, Moscow

References

  1. Juutilainen A. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004; 27: 2898-2904.
  2. The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur. Heart J. 2007; 28: 88-136.
  3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998; 317: 703-713.
  4. Adler A., Stratton I. M., Neil H. et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br. Med. J. 2000; 321: 412-419.
  5. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J. Hypertens. 2007; 25: 1105-1187.
  6. Stratton I. M., Adler A. I., Neil H. A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 2000; 321: 405-412.
  7. Marso S. P., Lincoff M., Ellis S. G. et al. Optimizing the percutaneous outcome for patients with diabetes mellitus. Results of the EPISCENT Diabetic Substudy. Circulation 1999; 100: 2477-2484.
  8. Marks J. B., Raskin P. Cardiovascular risk in diabetes. J. Diabet. Complicat. 2000; 14: 108-115.
  9. Norhammar A., Malmberg K., Ryden L. et al. Under-utilisation of evidence-based treatment partial explanation for the unfavorable prognosis in diabetic patients with acute myocardial infarction. Eur. Heart J. 2003; 24: 838-844.
  10. Дедов И. И., Александров А. А. Сердечно-сосудистая патология м сахарный диабет. Статины и "микрососудистая ишемия" миокарда. Consilium Medicum. 2004; 9: 4-9.
  11. Дедов И. И., Бондаренко И. З., Ахматова Ф. Д., Александров А. А. Кардиальная автономная нейропатия в диагностике ишемической болезни сердца у больных сахарным диабетом 1-го типа. Сахар. диабет. 2003; 4: 2-9.
  12. Otter W., Kleybrink S., Doerig W. et al. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabetes Med. 2004; 21: 183-187.
  13. De Groot M., Auslander W., Williams J. H. et al. Depression and poverty among african american women at risk for type 2 diabetes. Ann. Behav. Med. 2003; 25(3): 172-181.
  14. Malmberg K., Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur. Heart J. 1988; 9: 256-264.
  15. Gustafsson I., Hildebrandt P., Seibaek M. et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE. Study Group. Eur. Heart J. 2000; 21: 1937-1943.
  16. Angular D., Solomon S., Kober L. et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute miocardial infarction, the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Circulation 2004; 21: 1572- 1578.
  17. Goyal A., Mahaffey K., Gard J. et al. Prognostic significance of the change in glucose level in the first 24h after acute myocardial infarction, results from the CARDINAL study. Eur. Heart J. 2006; 27: 1289-1297.
  18. Bartnik M., Ryden L., Ferrari R. et al. Euro Heart Survei Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur. Heart J. 2004; 25: 1880-1890.
  19. Malmberg K., Norhammar A., Ryden L. et al. Glucometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999; 99: 2626-2632.
  20. Van den Berghe G., Wouters P. J., Weekers F. et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 2001; 345: 1359-1367.
  21. Malmberg K., Ryden L., Efendic S. et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J. Am. Coll. Cardiol. 1995; 26: 57-65.
  22. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br. Med. J. 1997; 314: 1512-1515.
  23. Myocardial infarction redefined-A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur. Heart J. 2000; 21: 1502-1516.
  24. De Backer G., Ambrosioni E., Borch-Johnsen K. et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2003; 24: 1601-1610.
  25. Liebl A., Mata M., Eschwege E. Evaluation of risk factors for development of complications in type 2 diabetes in Europe. Diabetologia 2002; 45: S23-S28.
  26. Brown J. B., Nichols G. A. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am. J. Manag. Care 2003; 9: 213-217.
  27. Gudbjernsdottir S., Cederholm J., Nilsson P. M. et al. The National Diabetes Register in Sweden: an implementation of the St Vincent declaration for quality improvements in diabetes care. Diabetes Care 2003; 26: 1270-1276.
  28. Malmberg K., Ryden L., Wedel H. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI2): effects on mortality and morbidity. Eur. Heart J. 2005; 26: 650-661.
  29. Van den Berghe G., Wouters P. J., Bouillon R. et al. Outcome benefit of insulin therapy in the critical ill: insulin dose versus glycemic control. Crit. Care Med. 2003; 31: 359-366.
  30. Gitt A., Schiele R., Wienbergen H. et al. MITRA study. Intensive treatment of coronary artery disease in diabetic patients in clinical pactice: results of the MITRA study. Acta Diabetol. 2003; 40: S343-S347.
  31. Schnell O., Doering W., Schefer O. et al. Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction. The Munich registry. Diabetes Care 2004; 27: 455-460.

Statistics

Views

Abstract - 47

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies